Technologies
A platform built around one question
Where is the exposure being lost? Poor oral bioavailability is rarely a single problem — it can stem from low solubility, slow dissolution, limited permeability, or first-pass metabolism. We characterise the rate-limiting step first, then deploy the enabling technology that resolves it. The technology serves the molecule, never the other way around.
Our approach
Format follows the molecule
We are technology-agnostic by design. A high-melting, brick-dust compound calls for a different solution than a lipophilic oil or a metabolically labile candidate, so we maintain genuine breadth across solubilisation, particle engineering, and crystal-form approaches.
Candidate technologies are screened in parallel on milligram quantities of API, ranked against developability and dose criteria, and confirmed with biorelevant dissolution and, where appropriate, in vivo PK before we commit a programme to a single path.
Enabling technologies
The bioavailability toolbox
A complementary set of solubilisation, particle-engineering, and crystal-form technologies — applied individually or in combination.
Spray-dried dispersions
Amorphous solid dispersions that hold the API in a high-energy, readily dissolving state — our workhorse for solubility-limited compounds, from feasibility to GMP.
Hot-melt extrusion
A solvent-free route to amorphous dispersions and modified-release matrices, well suited to thermally stable, high-dose molecules.
Lipid-based delivery
SEDDS and SMEDDS that present the drug pre-dissolved and can favour lymphatic uptake — helping lipophilic, first-pass-limited compounds reach systemic circulation.
Particle engineering
Micronisation and wet-bead nanomilling increase surface area to accelerate dissolution rate for permeability-adequate, dissolution-limited drugs.
Salt & co-crystal screening
Solid-form and salt selection to improve intrinsic solubility and stability before more complex enabling formulation is needed.
Predictive biopharmaceutics
Biorelevant dissolution and PBPK modelling link in vitro performance to predicted in vivo exposure, so we choose formulations on evidence, not intuition.
Principles
How we engineer for exposure
Diagnose before you formulate
Solubility, dissolution rate, permeability class, and metabolic liability are mapped first. The mechanism of low exposure dictates the technology — not house preference.
Developability by design
Physical stability, manufacturability, and dose loading are assessed alongside dissolution from the first screen, so promising formulations survive scale-up and shelf life.
Evidence over intuition
Biorelevant testing and PBPK modelling connect the bench to the clinic, de-risking the in vitro–in vivo leap before material and capital are committed.
Where this matters
Programmes we're built for
Low oral exposure
Compounds with suboptimal, variable PK driven by limited solubility or first-pass metabolism — where an enabling formulation can lift and stabilise systemic exposure enough to support a clean clinical readout.
Low-dose & potent molecules
Content-uniformity and handling challenges at low dose, including high-potency APIs requiring contained processing alongside bioavailability enhancement.
See how the platform maps to your stage
From a first feasibility screen to GMP clinical supply, our services flex to where your programme is today.